What Can We Expect to Learn from Canopy Growth's (CGC) Investor Meeting?

: CGC | Canopy Growth Corporation  News, Ratings, and Charts

CGC – Canopy Growth Corp., the largest cannabis company in the world by market cap, has had a few disappointing quarters recently.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Canopy Growth Corp., the largest cannabis company in the world by market cap, has had a few disappointing quarters recently, losing over $1 billion in the past 6 months. As a result, Canopy Growth is trading down 32% year-to-date.

On Friday MKM analyst Bill Kirk said that he believes Canopy Growth will not be profitable anytime soon. He said, “Unlike market expectations, we do not expect Canopy to become a profitable organization by FY2022.”

Kirk anticipates increased spending from the company. He also expects pressure on Canopy’s business in Canada as additional supply reaches the market. He said, “Current spending is the beginning of what is needed to capture future profitable opportunities. Existing cultivation businesses will continue to be under pressure as more supply comes online.”

Kirk recommended that analysts ask these 10 questions when attending Canopy Growth’s investor meeting today (12/3/19):

  1. How does the FDA’s updated stance on CBD impact your plans for CBD beverages in the U. S.?
  2. How much more labor do the 2.0 products require compared to the current portfolio?
  3. Is employee morale impacted by the plans to cut executive compensation?
  4. Why have your peers struggled to have a THC Beverage ready for 2.0?
  5. Has any industry opened 40 stores during a month in a single province?
  6. Compared to six months ago, have your plans for vape changed (marketing, resources, etc.)?
  7. With such low levels of oil inventory, do you have enough to meet 2.0 launch demands?
  8. What is most important for getting share from illicit (pricing, 2.0, enforcement, or quality)?
  9. What facilities are best for you to service Europe?
  10. Does STZ’s (Buy, $184.06, $256 PT) comment about no more cash contribution (aside from warrants) surprise you?

Personally, I’d like answers to all 10 questions but I am very focused on 3 particular topics.

  1. For the short term, we need clarification and confidence that we will actually see the expedited rollout of retail shops across Canada. If they can not deliver a stronger retail network for 2020 then we need realistic expectations for revenue and guidance.
  2. Examining how the the black market is affecting their business. It will contribute to profitability as black market consumers are converted to legal market consumers but Canopy Growth Corporation needs a real strategy in order to make this a reality.
  3. Canopy Growth Corporation needs to focus its efforts on international revenues as opposed to international research and development. They need to provide clarity as to how they will be a globally profitable cannabis company.

We know that Canopy Growth is a leader in the cannabis industry and we know it has a safety net that most of its peers don’t: its partnership with Constellation Brands (NYSE:STZ). But, as investors, what we need to see from today’s meeting is Canopy Growth’s path to profitability. Hopefully, we will get some clarity.


CGC shares were trading at $18.40 per share on Tuesday afternoon, up $0.26 (+1.43%). Year-to-date, CGC has declined -31.52%, versus a 25.18% rise in the benchmark S&P 500 index during the same period.

About the Author: Aaron Missere

Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CGCGet RatingGet RatingGet Rating
GNLNGet RatingGet RatingGet Rating
ACBGet RatingGet RatingGet Rating
CRONGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating
TLRYGet RatingGet RatingGet Rating
CTSTGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

: ACB | Aurora Cannabis Inc. Common Shares News, Ratings, and Charts

Is Now the Time to Buy Shares of Aurora Cannabis (ACB)?

In March of this year, the company's stock was up nearly 90% and had a $10 billion market cap. However, currently the company’s stock sits lower by 53%.
NASDAQ: CBOE | Cboe Global Markets, Inc.  News, Ratings, and Charts

The 6 Rookie Mistakes Options Traders Should Avoid

Today's featured article covers the 6 rookie mistakes options traders should avoid. Continue reading to find all about them.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

[Just Released] 2020 Stock Market Outlook

What is the target for the S&P 500 (SPY) in 2020? Better yet, what are the 3 elements of stocks likely to outperform in the year ahead? Get the answers to that and more in this 2020 Stock Market Outlook.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

3 Things Investors Need To Know About The Blowout Jobs Report

Today's featured article covers the three things investors need to know about the blowout jobs report. Continue reading for more details
NASDAQ: GWPH | GW Pharmaceuticals Plc News, Ratings, and Charts

Why Investors Should be Bullish About GW Pharmaceuticals (GWPH)

GW Pharmaceuticals (GWPH) has been on a steady downtrend since they reported their last quarterly earnings in November.

Read More Stories

More Canopy Growth Corporation (CGC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CGC News
Page generated in 2.2331 seconds.